Sanofi India (BOM:500674) Beneish M-Score: -3.14 (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500674 Sanofi India Ltd BOM:500674
77 GF Score
Price ₹3,369.25
GF Value ₹4,402.68
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sanofi India Beneish M-Score?

Sanofi India BOM:500674 -0.54% 77 Beneish M-Score is -3.14 as of Jul. 27, 2026. GuruFocus rates BOM:500674 with a GF Score™ of 77/100 and a GF Value™ of ₹4,402.68 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Sanofi India ranks better than 85.95% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.14 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sanofi India's Beneish M-Score or its related term are showing as below:

BOM:500674' s Beneish M-Score Range Over the Past 10 Years
Min: -3.14   Med: -2.23   Max: -0.87
Current: -3.14

During the past 13 years, the highest Beneish M-Score of Sanofi India was -0.87. The lowest was -3.14. And the median was -2.23.


Sanofi India Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sanofi India's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi India Beneish M-Score Chart

Sanofi India Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.13 -2.47 -1.16 -1.74 -3.14

Sanofi India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -3.14 0.00

BOM:500674 vs LLY, JNJ, ABBV: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Sanofi India's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi India Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi India's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sanofi India's Beneish M-Score falls into.


BOM:500674
77GF Score
Sanofi India Ltd BOM:500674
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi India Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sanofi India for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7125+0.528 * 0.9901+0.404 * 1.1305+0.892 * 0.9167+0.115 * 0.9877
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9456+4.679 * -0.088938-0.327 * 0.8645
=-3.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was ₹1,806 Mil.
Revenue was ₹18,234 Mil.
Gross Profit was ₹9,175 Mil.
Total Current Assets was ₹8,006 Mil.
Total Assets was ₹12,548 Mil.
Property, Plant and Equipment(Net PPE) was ₹3,177 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹373 Mil.
Selling, General, & Admin. Expense(SGA) was ₹1,393 Mil.
Total Current Liabilities was ₹4,914 Mil.
Long-Term Debt & Capital Lease Obligation was ₹137 Mil.
Net Income was ₹3,267 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹4,383 Mil.
Total Receivables was ₹2,765 Mil.
Revenue was ₹19,890 Mil.
Gross Profit was ₹9,909 Mil.
Total Current Assets was ₹11,268 Mil.
Total Assets was ₹16,118 Mil.
Property, Plant and Equipment(Net PPE) was ₹3,299 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹382 Mil.
Selling, General, & Admin. Expense(SGA) was ₹1,607 Mil.
Total Current Liabilities was ₹7,365 Mil.
Long-Term Debt & Capital Lease Obligation was ₹140 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1806 / 18234) / (2765 / 19890)
=0.099046 / 0.139015
=0.7125

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(9909 / 19890) / (9175 / 18234)
=0.49819 / 0.503181
=0.9901

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (8006 + 3177) / 12548) / (1 - (11268 + 3299) / 16118)
=0.108782 / 0.096228
=1.1305

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=18234 / 19890
=0.9167

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(382 / (382 + 3299)) / (373 / (373 + 3177))
=0.103776 / 0.10507
=0.9877

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1393 / 18234) / (1607 / 19890)
=0.076396 / 0.080794
=0.9456

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((137 + 4914) / 12548) / ((140 + 7365) / 16118)
=0.402534 / 0.465628
=0.8645

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3267 - 0 - 4383) / 12548
=-0.088938

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sanofi India has a M-score of -3.14 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.14 mean?
Sanofi India (BOM:500674) has a Beneish M-Score of -3.14 as of Jul. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sanofi India and its competitors. According to the industry distribution chart, Sanofi India ranks #128 out of 911 companies in the Drug Manufacturers industry, placing it in the top 14.1%.
Is Sanofi India's Beneish M-Score too high?
Sanofi India's current Beneish M-Score is -3.14. Based on the distribution chart, Sanofi India ranks #128 out of 911 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi India has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's Beneish M-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi India ranks #128 out of 911 companies for Beneish M-Score. This places Sanofi India in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sanofi India and its competitors. Sanofi India's current Beneish M-Score is -3.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (BOM:500674) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,402.68, compared to a current price of ₹3,369.25 — trading 23.5% below its estimated fair value. The current Beneish M-Score is -3.14. Sanofi India's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sanofi India (BOM:500674), the current Beneish M-Score is -3.14 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi India (BOM:500674) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued. The current stock price of ₹3,369.25 is trading 23.5% below its estimated GF Value™ of ₹4,402.68. GuruFocus considers Sanofi India to be Modestly Undervalued.

Key valuation signals for BOM:500674:

  • Beneish M-Score: -3.14
  • GF Value™: ₹4,402.68 vs. price of ₹3,369.25 (23.5% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanofi India Business Description

Other Exchanges SANOFI:India
Address Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score

Get the complete analysis for BOM:500674

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,369.25
Price
₹4,402.68
GF Value